Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends|Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A

The paroxysmal nocturnal hemoglobinuria (pnh) market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report

Segmentation & Regional Insights
The paroxysmal nocturnal hemoglobinuria (pnh) market covered in this report is segmented –

1) By Treatment Type: Medications; Bone Marrow Transplantation; Blood Transfusion; Immunosuppressive Therapy; Other Treatment Types
2) By Diagnosis Type: Flow Cytometry; High-Resolution Mass Spectrometry; Other Diagnosis Types
3) By End Use: Hospitals; Clinics; Other End Users

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2023. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp

Major Driver Impacting Market Growth
The rising number of blood disorders and bone marrow-related disorders is expected to propel the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market going forward. Blood disorders are medical conditions that affect the composition, function and production of blood and its components. Bone marrow-related disorders occur when either insufficient red, white, or platelet production occurs in the bone marrow or when the blood cells that are generated are damaged or defective. PNH is closely related to blood disorders and bone marrow-related disorders due to its impact on blood cell production, immune system function and the bone marrow microenvironment. It is a rare blood disorder that is related to bone marrow failure diseases and occurs when a genetic flaw affects how red blood cells and platelets work. For instance, in June 2021, according to the Leukemia Foundation, an Australia-based non-governmental organization, there are more than 110,000 people suffering from blood disorders in Australia. By the year 2035, more than 275,000 Australians are predicted to have blood disorders. Furthermore, in October 2022, according to the Cancer Data in Australia 2021 report published by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, more than 50 Australians will have a blood cancer diagnosis every day in 2021, up from 47 every day in 2020. Therefore, the rising number of blood disorders and bone marrow-related disorders is driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

Key Industry Players
Major players in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.

The paroxysmal nocturnal hemoglobinuria (pnh) market report table of contents includes:

1. Executive Summary

2.Paroxysmal Nocturnal Hemoglobinuria (PNH) Market  Characteristics

3.Paroxysmal Nocturnal Hemoglobinuria (PNH) Market  Trends And Strategies

4.Paroxysmal Nocturnal Hemoglobinuria (PNH) Market  – Macro Economic Scenario

5. GlobalParoxysmal Nocturnal Hemoglobinuria (PNH) Market Size and Growth

.

.

.

32. GlobalParoxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Benchmarking
33. GlobalParoxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Dashboard
34. Key Mergers And Acquisitions InParoxysmal Nocturnal Hemoglobinuria (PNH) Market

35.Paroxysmal Nocturnal Hemoglobinuria (PNH) Market  Future Outlook and Potential Analysis

36. Appendix

 

Top Major Players :

• Pfizer Inc.
• Johnson & Johnson Pvt Ltd.
• Hoffmann-La Roche AG.
• Novartis AG
• Sanofi S.A

 

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model